All stock lists
Unlock the score
MediWound Ltd. (NASDAQ:MDWD)
IL · Delayed Price · Currency is USD
Healthcare · Biotechnology
12.06+0.07 (+0.54%)
Market cap
$156M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 20, 2014
Website
Insider Score
/ 100
MDWD Insider Score
MediWound Ltd. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
Financial Health Score
Weak
From MDWD’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $11.9M
- Net income
- -$20.2M
- Net margin
- -170.1%
Leverage17 / 20
Little or no net debt.
- Total debt
- $9.5M
- Cash
- $4.3M
- Debt / equity
- 0.27
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $43.0M
- Current liabilities
- $18.5M
- Current ratio
- 2.32
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$22.0M
- Free cash flow
- -$28.4M
- FCF margin
- -239.3%
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 12.9M
- Share growth (1y)
- 18.9%
- Cash runway
- 2 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
MDWD Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 3.09 M | 1.48 M | 1.87 M | 5.43 M | 5.71 M | 3.96 M |
| Revenue Growth (YoY) | -45.83 % | -62.71 % | -68.03 % | 24.66 % | 12.74 % | -20.33 % |
| Cost of Revenue | 2.75 M | 1.15 M | 1.59 M | 4.53 M | 4.37 M | 3.22 M |
| Gross Profit | 337.00 K | 323.00 K | 278.00 K | 896.00 K | 1.34 M | 738.00 K |
| SG&A Expense | 3.89 M | 3.56 M | 3.33 M | 3.96 M | 3.57 M | 3.07 M |
| R&D Expense | 5.90 M | 5.18 M | 4.48 M | 3.46 M | 3.49 M | 2.89 M |
| Operating Expenses | 9.79 M | 8.30 M | 8.09 M | 7.42 M | 7.06 M | 5.96 M |
| Operating Income | -9.46 M | -7.98 M | -7.81 M | -6.53 M | -5.72 M | -5.22 M |
| Pretax Income | -7.36 M | -2.97 M | -7.11 M | -2.60 M | -13.28 M | -721.00 K |
| Tax Provision | 33.00 K | -17.00 K | 73.00 K | 53.00 K | 38.00 K | 5.00 K |
| Net Income | -7.39 M | -2.95 M | -7.18 M | -2.65 M | -13.32 M | -726.00 K |
| EPS (Basic) | -0.57 | -0.23 | -0.56 | -0.24 | -1.23 | -0.07 |
| EPS (Diluted) | -0.57 | -0.23 | -0.56 | -0.24 | -1.23 | -0.07 |
| Shares Outstanding | 12.88 M | 12.87 M | 12.83 M | 11.02 M | 10.84 M | 10.37 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.